The role of pneumococcal (Pnc) surface adhesin A (PsaA) in the adherence of Streptococcus pneumoniae (pneumococcus) to host cells is not well defined. We examined the effect of anti-PsaA antibodies in an inhibition of adherence assay using Detroit 562 nasopharyngeal human epithelial cells. Rabbit polyclonal (Pab) anti-recombinant PsaA (rPsaA) sera, a purified mouse monoclonal antibody (MAb) (MAb 6F62G8E12), and 22 healthy adult sera with known anti-PsaA IgG levels (obtained by enzyme-linked immunosorbent assay) were evaluated for their abilities to inhibit Pnc adherence to confluent monolayers (measured as percent reduction in CFU counts compared to those of uninhibited controls). Pnc adherence was dependent on capsular phenotype (no or low adherence for opaque strains). With an inoculum of 10 4 to 10 5 bacteria/well, the mean ؎ standard deviation count in controls was 163 ؎ 32 CFU/well for transparent strains. Low adherence was observed for a PsaA-minus mutant even at higher inoculum doses. Mean percent inhibitions of adherence with Pab and MAb were 54 and 50%, respectively. Adult sera showed inhibition in a dose-response fashion with a range of 98 to 8%, depending on the serum anti-PsaA antibody concentration. Absorption of Pab with rPsaA restored Pnc adherence to control levels. Absorption of sera with a PsaA-minus mutant did not result in a significant decrease (P >0.05) of inhibition of adherence activity. Additionally, nearly 100% of Pnc adherence was inhibited by lipidated rPsaA at 2.5 g/ml. Our data support the argument that PsaA is an adhesin that mediates Pnc adherence to human nasopharyngeal cells. This functional assay may be useful in evaluating antibodies elicited in response to PsaA vaccination.
Streptococcus pneumoniae (pneumococcus) is one of the leading causes of infant mortality worldwide. The high rates of disease observed after infections with this bacterium are largely due to the fact that humans of all ages can be colonized by pneumococcus. Some persons develop disease after colonization, whereas others remain asymptomatic carriers. In an effort to reduce the burden of pneumococcal (Pnc) disease, multiple vaccine formulations have been developed based upon the immunogenicity that is generated by the type-specific capsular polysaccharides. Currently, two types of formulations are licensed in the United States, a 23-valent polysaccharide vaccine and a 7-valent protein conjugated-polysaccharide vaccine (5, 8, 9) . The conjugated-polysaccharide vaccines have been shown to reduce Pnc colonization in some populations (14) . However, there is still the risk of replacement (infection with other serotypes not included in the vaccine) (S. K. Obaro, R. A. Adegbola, W. A. S. Banya, and B. M. Greenwood, Letter, Lancet 348:271-272, 1996) and serotype switching (natural genetic transformation from one serotype to another) (10) . There is a possibility for unmasking of nonvaccine serotypes present at lower levels than the vaccine serotype (19) . In addition, the serotype coverage of the conjugated-polysaccharide vaccines is limited depending on the geographic area.
A third generation of Pnc vaccines is under development. These vaccines are based on common proteins (present in all 90 known Pnc serotypes) that are immunogenic in humans after infection and in vaccinated animals (6) . The candidate proteins for these vaccines are primarily Pnc surface adhesin A (PsaA), Pnc surface protein A (PspA), pneumolysin (Ply), and PspC, although other common proteins are currently under investigation (3, 6, 22) . PsaA is a putative Pnc adhesin and an ABC transporter for manganese (16) . The role of naturally developed antibodies to PsaA in prevention of colonization in humans has been previously demonstrated (24) . Anti-PsaA antibodies can reduce Pnc colonization and carriage in mice and protect chinchillas from otitis media (6; S. I. Pelton, M. Figueira, R. Albut, and J. Reino, Program Abstr. 2nd Int. Symp. Pneumococci Pneumococcal Dis. 2000, abstr. O38, 2000) . Other studies of mice have indicated that antibodies to PsaA can prevent colonization, whereas antibodies to PspA, for example, can reduce bacteremia and pneumonia. When both proteins are combined, a much higher level of protection was observed in mice (6, 22) . A recent report demonstrated protection in mice against Pnc lung colonization and septicemia after oral immunization with PsaA (29) .
Although the immune response to PsaA antibodies can be measured by enzyme-linked immunosorbent assay (ELISA), there is the need for the development of functional assays that measure the in vivo biological activity of the antibodies formed in response to vaccination. This study demonstrates that antiPsaA antibodies naturally developed in humans or elicited by recombinant PsaA (rPsaA) in animals can prevent the adherence of pneumococci to nasopharyngeal epithelial cells. This inhibition of adherence assay can be used for the measurement of the functional activity of anti-PsaA antibodies. Other Pnc strains were obtained from invasive isolates sent to the Centers for Disease Control and Prevention (CDC) for bacterial identification and serotyping (strains provided by Richard Facklam, Streptococcal Reference Laboratory, CDC). All strains were screened for their phenotypic expression of opacity factors, following the methodology described by Weiser et al. (31) . Only strains that were transparent in phenotype were used for adherence studies (12) . Transparent strains have been reported to have a lower capsular polysaccharide content than opaque strains (17) . We selected both well-characterized transparent strains which are nearly 100% transparent as previously described (17) and recent nasopharyngeal isolates (O'Brien et al., Abstr. 70th Annu. Meet. Soc. Pediatr. Res. 2001) for which Ն75% of the colonies were of the transparent phenotype. A complete list of strains used in this study is given in Table 1 . Pnc strains were grown in Todd-Hewitt broth supplemented with 0.5% yeast extract to an optical density at 420 nm of 0.4 to 0.6 (mid-logarithmic growth phase for the majority of strains tested) and stored frozen in the same medium after addition of 15% sterile glycerol. Viability of these frozen Pnc stocks for adherence assays was determined to be as long as 8 months.
Tissue culture cells. Nasopharyngeal human carcinoma epithelial cells (Detroit 562 cells) were purchased from the American Type Culture Collection, Manassas, Va. (CCL138). Cells were thawed and reconstituted in minimal essential medium with Earle's salts (EMEM) and without L-glutamine (Life Technologies, Grand Island, N.Y.) supplemented with 10% fetal calf serum (HyClone, Logan, Utah). Cells were grown in 75-cm 2 tissue culture bottles (Corning Costar Co., Cambridge, Mass.) at 37°C and in a 5% CO 2 atmosphere. After a period of 6 days cells reached confluency and were passed to a new culture flask and/or seeded to 96-well tissue culture treated plates (Corning Costar Co., Corning, N.Y.) for use in the adherence assays. Only confluent monolayers were used for the adherence assays. When monolayers that were only ϳ90% confluent were used, there was a loss of integrity of the monolayer, resulting in lower numbers of adherent CFU. Monolayers that were 1 to 2 days older than the maximum confluence period maintained integrity during the performance of the assay; however, there was higher variability in the number of adherent CFU. Cell monolayers were released by incubation with 0.05% trypsin solution and 0.53 mM EDTA (Life Technologies) for 10 to 15 min at 37°C. To enhance the effect of the trypsin-EDTA solution, all of the culture medium was removed and the monolayer was initially rinsed with 2 ml of the trypsin-EDTA solution, which was immediately discarded, and an additional 2 ml of trypsin-EDTA was added. A 70-ml volume of fresh tissue culture medium was added to the trypsin-treated monolayers, and the cells were gently resuspended in a single-cell suspension before counting of the viability by trypan blue (0.4%) exclusion. Technologies) and supplemented with 0.2% bovine serum albumin. Bacteria were allowed to adhere to the monolayer by incubation at 37°C for 2 h without shaking in a 5% CO 2 atmosphere. Time course experiments for optimal adherence were conducted with 30-min intervals ranging from 0.5 to 3 h by incubation of the infected monolayers with 10 4 bacteria/well. After the 2-h incubation period, an average of 150 to 200 CFU adhered to each well. Nonadherent bacteria were removed by five washes with phosphate-buffered saline (200 l/well; 100 mM, pH 7.2) supplemented with 0.2% bovine serum albumin (Sigma Chemical Co., St. Louis, Mo.). Extended incubation periods (Ͼ2 h) resulted in higher adherence rates and lower percentages of inhibition by the test sera (data not shown). Monolayers were maintained moist at all times, so a thin film of buffer was left after each wash, and plate covers were replaced in between washes. A 65-l volume of bacterial growth medium cooled to 42°C was added to each microtiter well. The bacterial growth medium was composed of Todd-Hewitt broth supplemented with 0.5% yeast extract, 0.5% agar, and 0.1% 2,3,5-triphenyl tetrazolium chloride (Difco Laboratories Inc., Detroit, Mich.) for improved visualization of CFU. Microtiter plates were allowed to solidify before incubation overnight at 37°C and in a 5% CO 2 atmosphere. Adherent CFU were quantitated by manual count under a stereoscope or by use of an automated colony counter (AlphaImager; Alpha Innotech, San Leandro, Calif.). Higher coefficients of variance were found in the outer wells of the microtiter plate, rows A and H and columns 1 and 12; therefore, these wells were not used for adherence assays, even if confluent cell growth was observed. These wells were washed and treated similarly and served as sterility and cross-contamination controls for each plate. Wells without inoculum helped in determining if the monolayers maintained integrity during the entire assay.
Inhibition of adherence. Six 10-fold dilutions of test serum were performed in a 100-l final volume in sterile microtiter plates. A 40-l volume of bacterial suspension usually containing 2 ϫ 10 4 bacteria per well was added to the diluted sera and allowed to incubate for 15 min at 37°C and in a 5% CO 2 atmosphere. The initial bacterial inoculum was adjusted for some Pnc serotypes (10 3 bacteria/ well for serotype 23F and 10 5 bacteria/well for serotype 18C) to yield an average of 150 CFU/well. However, for most serotypes 10 4 bacteria/well was a sufficient inoculum to yield enough adherent CFU per well. Seventy microliters of this mixture was transferred to the washed tissue culture monolayers containing 80 l of EMEM. Assays were run in duplicate for each serum sample. The remainder of the assay was performed as described above for adherence assays. Colony counts for each well were compared to the mean of the adherence control wells (12 wells, columns 2 and 11 in the microtiter plate). The percent inhibition of adherence was calculated for each serum sample as well as for reaction mixtures containing various concentrations of lipidated rPsaA (15) . Inhibitions of adherence were only calculated if the mean adherence in the control wells was between 2 standard deviations (SD) of the calculated mean adherence for a given target strain, as shown in Table 1 .
The following parameters were found to be optimal for assay performance: (i) confluent cell monolayers grown for 6 days in 96-well microtiter plates, (ii) use of EMEM for initial washing of the monolayers, (iii) addition of EMEM (80 l) to monolayers immediately after the initial washes, (iv) use of a bacterial dilution that yields 120 to 150 adherent CFU per well, (v) serum dilutions starting at 10 Ϫ1 , (vi) a 2-h incubation period to allow for bacterial adherence, and (vii) a minimum of five washes to remove nonadherent bacteria. Although we primarily used a 10-fold serum dilution scheme, other dilution schemes (two-, three-, or five-fold) have been tested successfully. This parameter can be varied according to the serum antibody levels.
Serum samples. Rabbit polyclonal (Pab) sera specific for the lipidated rPsaA protein (15), a purified mouse monoclonal antibody (MAb) (MAb 6F62G8E12) (11) , and normal adult sera (n ϭ 3 ]-phosphate-buffered saline. Doses were given 3 weeks apart, and animals were bled 21 days after dose 1 and 25 days after dose 2. Preimmunization serum was collected 5 days prior to dose 1. Normal healthy donor sera (age range, 24 to 62 years) were obtained through the Emory donor services, Atlanta, Ga. Sera were stored frozen at Ϫ70°C in 100-l aliquots until ready to use. The ELISA methodology used was previously reported (24, 30) . Anti-PsaA IgG concentrations determined by ELISA were calculated in micrograms per milliliter and compared to the U.S. National Reference Preparation (USNRP no. IS1644; Centers for Disease Control and Prevention, Atlanta, Ga.) used for determinations of specific human serum proteins (25) and after cross-standardization against the Food and Drug Administration (Bethesda, Md.) reference serum lot 1983 standard (anti-polyribosyl-ribitol phosphate IgG antibodies [60.9 g/ml]) for Haemophilus influenzae type b (20) .
Statistical analysis. Inhibition of Pnc adherence was calculated as percent reduction in CFU counts per well compared to uninhibited adherence controls. Significant differences between two sets of data were calculated by the t test, with significance defined as a P of Ͻ0.05. The Mann-Whitney rank sum test was used when the data were not normally distributed. Antibody concentrations determined by ELISA were calculated against a standard curve using the four-parameter logistic log curve-fitting technique (23) . The Pearson product moment correlation coefficient was used for comparison among anti-PsaA antibody concentrations and the percent inhibition of adherence. A weighted average of the percent inhibition of adherence observed with a given serum sample was calculated by using the log 10 of each serum dilution factor as the weight.
RESULTS
Pnc adherence. Pnc adherence to nasopharyngeal epithelial cells (Detroit 562) was dependent on capsular phenotype as previously described for other epithelial cells by Cundell et al. (12) . There was very low or no adherence for opaque strains regardless of the serotype. The opaque phenotype correlates with high capsular polysaccharide content (17) . On the other hand, transparent or intermediate strains demonstrated high adherence to Detroit 562 cells. With an inoculum of 10 4 bacteria/well, the mean count Ϯ 1 SD for adherence controls was 163 Ϯ 32 CFU/well (coefficient of variation ϭ 20%; n ϭ 420 wells) for transparent strains. In general, the invasive Pnc strain isolates were opaque and the nasopharyngeal Pnc strain isolates were transparent or exhibited a mixture of opaque and transparent colonies. Differential adherence to Detroit 562 cells depending on the strain used is shown in Table 1 . Transparent strains of different serotypes appeared to have the same capacity to adhere. Addition of type-specific polysaccharide (500 g/ml) to the reaction mixture did not result in reduced adherence. However, low adherence (mean ϭ 23 CFU) was observed for a PsaA-minus mutant even at higher inoculum doses of 10 6 bacteria/well. The absence of the PsaA protein in this mutant was confirmed by negative colony blot staining with the anti-PsaA mouse MAb (MAb 6F62G8E12) and resistance to erythromycin (Յ0.2 g/ml), as previously reported by Berry and Paton (4). Pnc adherence was successfully obtained with tissue cultures of high passage number (passage numbers evaluated were between 40 and 120).
Inhibition of Pnc adherence. Mean percent inhibition of adherence for five transparent strains with a selected Pab (10 Ϫ5 dilution) was 54%. Figure 1A gives the mean percent inhibition of adherence obtained with three preimmunization and three Pab rabbit sera for Pnc serotype 19F. No inhibition of adherence was detected in pooled baby rabbit serum or in nonimmunized rabbits. Figure 1B gives the inhibition of adherence (serotype 19F) observed with MAb with and without absorption with the PsaA minus mutant. No significant change (P ϭ 0.95) in the inhibition of adherence was observed after absorption with this mutant. Absorption of a 10 Ϫ2 dilution of Pab, MAb, and a human serum with a high anti-PsaA concentration with rPsaA (0.5 g) restored Pnc adherence to control levels for Pab and for the human serum; however, the inhibitory activity of MAb could only be absorbed by 61% (data not shown). Healthy adult donor sera showed inhibition in a doseresponse fashion with a range of 98 to 8%, depending on the serum anti PsaA antibody concentration, Fig. 2 . The adherence of multidrug-resistant strains, serotype 19A (91/6571) and serotype 23F (SP264), was inhibited 95 and 78% (respectively) by healthy human sera (average inhibition of a 1:10 serum dilution from donors 259 and 7047). Sera with high levels of antiPsaA antibodies needed to be diluted further to observe the linear portion of the inhibition of adherence. Therefore, it was necessary to use 10-fold-dilution schemes instead of twofolddilution schemes when testing for serum inhibitory activity.
Specificity of the inhibition of Pnc adherence. The inhibition of Pnc serotype 19F adherence by selected human sera before or after the absorption with the PsaA-minus strain was determined. Absorption (30 min at room temperature) of human sera (100 l) with a PsaA-minus mutant pellet containing 10 8 CFU did not result in a significant decrease (P ϭ 0.11, paired t test) of the maximum percent inhibition of Pnc adherence to Detroit 562 cells. The mean percent inhibition of adherence Ϯ SD for unabsorbed and absorbed sera (n ϭ 18) was 72% Ϯ 18% and 68% Ϯ 16%, respectively. Addition of Ն2.5 g rPsaA/ml (Ն0.25 g/well) to confluent cell monolayers 15 min prior to the addition of S. pneumoniae can block nearly 100% of Pnc adherence (Fig. 3) . No significant effect was seen by direct addition of homologous Ps type 18C (500 g/well) to the monolayers prior to addition of bacterial inoculum. Effect of cell wall polysaccharide addition (250 g/well) was not significant if the strains were encapsulated; however, addition of cell wall polysaccharide (preincubation of monolayers with 100 g/ well for 15 min at room temperature) to rough controls (R36A unencapsulated strain) resulted in a significant decrease in adherence of this strain.
Reproducibility among Pnc serotypes. The maximum inhibitions of adherence (mean Ϯ SD) observed with five human sera (1:10 dilution) for serotypes 2, 6A, 18C, 19F, and 23F were 74% Ϯ 14%, 67% Ϯ 19%, 65% Ϯ 7%, 83% Ϯ 18%, and 73% Ϯ 29%, respectively. There was no significant difference (P Ͼ 0.05) in the maximum percentages of inhibition among differ-ent serotypes. Within serotype coefficients of variance for adherence were calculated to be 18 to 25% depending on the serotype.
Correlation with ELISA IgG levels. The overall correlation (r ϭ 0.73) of anti-rPSA IgG antibodies (in micrograms per milliliter, as determined by ELISA) and the weighted average of the percent inhibition of adherence were significant (P Ͻ 0.05), as shown in Fig. 4 . In general, a trend was observed that human serum samples with high inhibiting activity also had high anti-rPsaA IgG concentrations as shown by ELISA.
DISCUSSION
PsaA was first discovered in Pnc by Russell et al. (27) . This protein is highly immunogenic and is conserved across all 90 serotypes of S. pneumoniae. These characteristics made PsaA a good candidate for a Pnc common protein vaccine to be used alone or in combination with other common protein antigens. Although serum antibody levels can be measured by ELISA (30) , this is the first study describing an assay for the measurement of functional activity elicited by PsaA. (4) . Experiments were performed with Pnc serotype 19F (strain 6133). Postimmunization pooled sera were highly reactive with rPsaA by Western blot analysis at a dilution of 1:128,000. Abbreviations: Pre, preimmunization rabbit sera (n ϭ 3, each serum tested in duplicate); Pab, postimmunization rabbit sera (n ϭ 3, each serum tested in duplicate). (B) Mean percent inhibition of adherence (Ϯ standard error [error bars]) to Detroit 562 cell monolayers by a purified mouse MAb, 6F62G8E12 (1.4 mg/ml), specific for PsaA (11) . Absorption of MAb with a PsaA-minus mutant (4) yielded similar inhibition of adherence (P ϭ 0.95, t test). Three independent experiments with Pnc serotype 19F (strain 6133) were performed in duplicate to calculate the means for absorbed and unabsorbed MAb. The inhibitory effect of rPsaA and both human and animal anti-PsaA antibodies on Pnc adherence to nasopharyngeal epithelial cells was demonstrated with this functional assay. This inhibitory effect was observed across multiple serotypes, and it was not restricted to a particular Pnc strain. In general, a higher CFU count was observed with transparent strains than with opaque strains, in agreement with previous colonization studies by Cundell et al. (12) . Preliminary studies indicate that there are no major differences in PsaA protein expression between these two phenotypes (data not shown). Weiser et al. reported that other surface proteins such as the amidase LytA are found at higher levels in the transparent phenotype than in the opaque phenotype (31) .
The role of PsaA as a potential Pnc adhesin was first demonstrated by Berry and Paton by the low adherence to type II pneumocytes observed with a PsaA-minus mutant (4). This mutant was also used in this study with similar low adherence for nasopharyngeal cells. However, the inhibitory effect in Pnc adherence by the purified lipidated rPsaA protein is described for the first time in this study. (29) . This type of protection in mice had not been observed previously. Phase 1 trials with humans have been conducted for PspA and will eventually be conducted for PsaA. A surveillance study in Finland demonstrated that incidence of otitis media was lower for children with higher levels of antiPsaA antibodies and higher for those children with lower levels of anti-PsaA antibodies (24) . While production of antibodies to Pnc proteins is age dependent (18, 24) , it is likely that the presence of anti-PsaA antibodies prevents colonization and therefore transmission of pneumococcus. The results of this study suggest that natural exposure to Pnc induces anti-PsaA antibody levels with functional activity (up to 98% inhibition of adherence in healthy adult donor sera). However, the induction of higher antibody levels postvaccination remains to be determined. Since PsaA is present in all Pnc serotypes (11, 21) , a vaccine including this protein may provide wider serotype coverage than those formulations that confer protection against a limited number of serotypes. Future vaccine evaluation will require the use of assays that measure not only the quantity of the antibodies elicited by the vaccine antigen but also the functional activity of such antibodies. In the case of Pnc polysaccharide antigens, such assays (ELISA and opsonophagocytosis assay) have been identified and standardized. However, for evaluating responses to Pnc protein antigens, these assays have not been established. In addition, the type of functional assay may vary depending on the protein function. Although Pnc adherence can be mediated by multiple adhesins, our data support the role of PsaA in Pnc adherence to human cells and the argument that this protein is a major Pnc adherence factor regardless of the serotype tested. This functional assay may be useful in evaluating antibodies elicited in response to PsaA vaccination. FIG. 4 . Correlation of functional antibody activity as measured by the weighted average of the percent inhibition of adherence and ELISA concentration of anti-PsaA IgG antibodies naturally found in human donor sera (n ϭ 22). A weighted average of the percent inhibition of adherence observed with a given serum sample was calculated by using the log 10 of each serum dilution factor as the weight. Analysis by the Pearson product moment correlation coefficient yielded a significant (P Ͻ 0.05) level of correlation (r ϭ 0.73) between the calculated weighted average of the percent inhibition and the measured anti-PsaA IgG concentration of the human serum. Inhibition assays were performed with either Pnc serotype 18C or 19F.
